Intrust Bank NA Sells 38 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Intrust Bank NA trimmed its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,736 shares of the company’s stock after selling 38 shares during the quarter. Intrust Bank NA’s holdings in IDEXX Laboratories were worth $964,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Valley National Advisers Inc. lifted its holdings in IDEXX Laboratories by 84.6% in the fourth quarter. Valley National Advisers Inc. now owns 48 shares of the company’s stock valued at $26,000 after acquiring an additional 22 shares during the period. OFI Invest Asset Management bought a new position in shares of IDEXX Laboratories in the 3rd quarter worth approximately $25,000. Venturi Wealth Management LLC grew its position in IDEXX Laboratories by 226.3% during the fourth quarter. Venturi Wealth Management LLC now owns 62 shares of the company’s stock valued at $34,000 after buying an additional 43 shares during the period. Geo Capital Gestora de Recursos Ltd bought a new stake in IDEXX Laboratories during the third quarter valued at approximately $28,000. Finally, Covestor Ltd increased its holdings in IDEXX Laboratories by 71.8% during the third quarter. Covestor Ltd now owns 67 shares of the company’s stock valued at $29,000 after buying an additional 28 shares during the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on IDXX shares. Barclays boosted their price objective on shares of IDEXX Laboratories from $605.00 to $655.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Piper Sandler downgraded shares of IDEXX Laboratories from an “overweight” rating to a “neutral” rating and set a $525.00 price objective on the stock. in a research report on Tuesday, January 30th. William Blair restated an “outperform” rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. JPMorgan Chase & Co. increased their price target on IDEXX Laboratories from $600.00 to $630.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Finally, The Goldman Sachs Group upped their price objective on IDEXX Laboratories from $500.00 to $650.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and an average price target of $591.50.

Insider Activity

In other news, SVP George Fennell sold 8,198 shares of the stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total value of $4,704,586.26. Following the sale, the senior vice president now directly owns 6,712 shares in the company, valued at $3,851,815.44. The sale was disclosed in a document filed with the SEC, which is available at this link. In related news, CEO Jonathan Jay Mazelsky sold 12,000 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the sale, the chief executive officer now directly owns 79,247 shares of the company’s stock, valued at $45,377,624.67. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP George Fennell sold 8,198 shares of IDEXX Laboratories stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $573.87, for a total value of $4,704,586.26. Following the transaction, the senior vice president now owns 6,712 shares of the company’s stock, valued at $3,851,815.44. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 43,524 shares of company stock valued at $24,871,960. 2.18% of the stock is currently owned by company insiders.

IDEXX Laboratories Price Performance

NASDAQ:IDXX traded down $0.77 during trading hours on Tuesday, reaching $504.57. The stock had a trading volume of 74,776 shares, compared to its average volume of 426,841. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.17 and a current ratio of 1.57. The stock has a market capitalization of $41.90 billion, a PE ratio of 50.18, a PEG ratio of 3.85 and a beta of 1.26. IDEXX Laboratories, Inc. has a 52 week low of $372.50 and a 52 week high of $583.39. The company has a 50 day moving average price of $530.02 and a two-hundred day moving average price of $512.17.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, February 5th. The company reported $2.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.12 by $0.20. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. The firm had revenue of $901.60 million for the quarter, compared to analysts’ expectations of $891.88 million. During the same period in the prior year, the company earned $2.05 EPS. The business’s revenue was up 8.8% compared to the same quarter last year. As a group, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.14 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.